ArticleNucleic acids research2023
The Cancer Epitope Database and Analysis Resource (CEDAR).
Article in Nucleic acids research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A meta-analysis of experimentally validated neo-epitopes: patterns, biases, and opportunities.Cancer immunology, immunotherapy : CII · 2025Pooled it
- A meta-analysis of epitopes in prostate-specific antigens identifies opportunities and knowledge gaps.Human immunology · 2023Pooled it
- Toward next-generation therapeutic HPV vaccines: A review on expanding the antigen repertoire and an integrated bioinformatics selection framework.Human vaccines & immunotherapeutics · 2026Review
- Pan-cancer analysis identifies immunoproteasome as the predominant survival-associated component of antigen processing machinery.Translational oncology · 2026Article
- Technical review of artificial intelligence in TCR-T therapy.Journal of the National Cancer Center · 2026Review
- The challenge and promise of studying human antigen-specific T cells.Nature reviews. Immunology · 2026Review
- Cancer epitope prediction tools and analysis pipelines in CEDAR.Nucleic acids research · 2026Article
- Revised Adaptive Immune Receptor Data in the Immune Epitope Database.bioRxiv : the preprint server for biology · 2026Article
- A structure-informed deep learning framework for modeling TCR-peptide-HLA interactions.bioRxiv : the preprint server for biology · 2026Article
- iPepGen: a modular, immunopeptidogenomic analysis pipeline for discovery, verification, and prioritization of cancer peptide neoantigen candidates.Genome biology · 2026Article
- Tumour-intrinsic features shape T cell differentiation through precursor to symptomatic multiple myeloma.Nature communications · 2026Article
- NeoPrecis: enhancing immunotherapy response prediction through integration of qualified immunogenicity and clonality-aware neoantigen landscapes.Nature communications · 2026Article
- B-cell epitope prediction in the age of machine learning: advancements and challenges.Journal of translational medicine · 2026Review
- The Cancer Epitope Database and Analysis Resource (CEDAR): current capabilities and future directions.Frontiers in oncology · 2026Review
- Artificial intelligence in peptide cancer vaccine design: from neoantigen discovery to immunogenicity prediction.Frontiers in genetics · 2026Review
- PredIG: an interpretable predictor of T-cell epitope immunogenicity.Genome medicine · 2025Article
- Informatics at the Frontier of Cancer Research.Cancer research · 2025Review
- Sensitive neoantigen discovery by real-time mutanome-guided immunopeptidomics.Nature communications · 2025Article
- NeoPrecis: Enhancing Immunotherapy Response Prediction through Integration of Qualified Immunogenicity and Clonality-Aware Neoantigen Landscapes.bioRxiv : the preprint server for biology · 2025Article
- Computation strategies and clinical applications in neoantigen discovery towards precision cancer immunotherapy.Biomarker research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
We established The Cancer Epitope Database and Analysis Resource (CEDAR) to catalog all epitope data in the context of cancer. The specific molecular targets of adaptive T cell and B cell immune responses are referred to as epitopes. Epitopes derived from cancer antigens are of high relevance as they are recognized by anti-cancer immune cells. Detailed knowledge of the molecular characteristic of cancer epitopes and associated metadata is relevant to understanding and planning prophylactic and therapeutic applications and accurately characterizing naturally occurring immune responses and cancer immunopathology. CEDAR provides a freely accessible, comprehensive collection of cancer epitope and receptor data curated from the literature and serves as a companion site to the Immune Epitope Database (IEDB), which is focused on infectious, autoimmune, and allergic diseases. CEDAR is freely accessible at https://cedar.iedb.org/.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.